Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul;593(13):1580-1597.
doi: 10.1002/1873-3468.13487.

Urinary exosomal proteins as (pan-)cancer biomarkers: insights from the proteome

Leyla Ayse Erozenci  1   2 , Franziska Böttger  1   2 , Irene V Bijnsdorp  2   3 , Connie R Jimenez  1   2
Affiliations
Free article

Urinary exosomal proteins as (pan-)cancer biomarkers: insights from the proteome

Leyla Ayse Erozenci et al. FEBS Lett. 2019 Jul.
Free article

Abstract

Exosomes are extracellular vesicles (EVs) released from cells under both physiological and pathological conditions, and may, thus, be present in biofluids. Urine is one of the most accessible biofluids implemented in clinical diagnostics. Recent mass spectrometry (MS)-based proteomic analyses have enabled high-throughput, deep proteome profiling of urinary EVs for the discovery, quantification and characterization of cancer-specific exosome biomarkers. The protein cargo of urine exosomes is emerging as an attractive source for biomarkers, not only for urological cancers, such as prostate, bladder and kidney cancer, but potentially also for nonurological cancers, including gastric, lung, oesophageal and colorectal cancer. More recently, exosome proteomics dissected protein cargo in the lumen and at the surface of EVs, and unexpectedly indicated that RNA- and DNA-binding proteins might also be present on vesicular surfaces. Here, we analyse MS-based proteomic data on urinary exosomes from cancer patients, and discuss the potential of urinary exosome-derived biomarkers in cancer.

Keywords: cancer; exosomes; extracellular vesicles; mass spectrometry; proteomics; urine.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Siravegna G, Marsoni S, Siena S and Bardelli A (2017) Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol 14, 531-548.
    1. Wang H, Shi T, Qian W-J, Liu T, Kagan J, Srivastava S, Smith RD, Rodland KD and Camp DG (2016) The clinical impact of recent advances in LC-MS for cancer biomarker discovery and verification. Expert Rev Proteomics 13, 99-114.
    1. Geyer PE, Holdt LM, Teupser D and Mann M (2017) Revisiting biomarker discovery by plasma proteomics. Mol Syst Biol 13, 942.
    1. Huang R, Chen Z, He L, He N, Xi Z, Li Z, Deng Y and Zeng X (2017) Mass spectrometry-assisted gel-based proteomics in cancer biomarker discovery: approaches and application. Theranostics 7, 3559-3572.
    1. Böttger F, Schaaij-Visser TB, de Reus I, Piersma SR, Pham TV, Nagel R, Brakenhoff RH, Thunnissen E, Smit EF and Jimenez CR (2019) Proteome analysis of non-small cell lung cancer cell line secretomes and patient sputum reveals biofluid biomarker candidates for cisplatin response prediction. J Proteomics 196, 106-119.

Publication types

Substances

LinkOut - more resources